IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	)	Art Unit:
GELLERFORS, et al.	)	Examiner:
Serial No.: Not yet known	)	Washington, D.C.
Filed: Even date herewith	)	January 28, 2002
For: PRODUCTION OF rhPBGD AND NEW THERAPEUTIC METHODS FOR TREATING PATIENTS..	)	Docket No.: GELLERFORS=2

PRELIMINARY AMENDMENT

Commissioner of Patents
Washington, D.C. 20231

S i r :

IN THE CLAIMS

Please amend claims 2, 4, 6, 7, 9, 10, and 11 as follows:

2 (amended). A method for the preparation of rhPBGD by a method comprising

(a) providing a vector comprising an expressible nucleic acid sequence encoding PBGD;

(b) culturing the transformed host cell under conditions facilitating expression of the nucleic acid sequence;

(c) recovering the expression product from the culture.

4 (amended). A method according to claim 2 further comprising a purification step.

6 (amended). A method according to claim 2, wherein the PBGD is recombinant human PBGD encoded by Seq. ID NO 3 (clone PBGD 1.1) or Seq. ID NO 4 (non-erythro PBGD 1.1.1).

7 (amended). An expression plasmid pExp1-M2-BB as shown in Seq. ID NO 1.

9 (amended). A rhPBGD produced by the method of claim 2 and able to lower the levels of PBG and ALA in mice during an acute attack of porphyria in a transgenic mouse model where the PBGD gene has partially been knocked-out.

10 (amended). A rhPBGD having a stability of at least 6 weeks at 20°C.

11 (amended). A rhPBGD having a stability resulting in a decrease in activity of less than 10% per month.

Please add the following new claims:

12 (new). A genetically modified bacterial cell which does